Abstract
As the epidemic of overweight and obesity spreads, the number of individuals at risk for metabolic complications of obesity, including cardiovascular disease, type 2 diabetes, and cancer, is expected to increase. Importantly, the risks of complications are not evenly distributed, because not all obesity is biochemically identical. Here we describe “metabolically healthy obese” humans and animal models that show remarkable protection from insulin resistance and glucose intolerance, despite severe obesity. A hallmark of these patients and animals is their reduced inflammatory profile, which we hypothesize confers protection not only from cardiometabolic risk in obesity but also from obesity-associated cancers. Research is urgently required to investigate the basis for this protection, to identify treatment options and prevention strategies for at-risk populations. We explore novel insights into chromatin-based, transcriptional co-regulator mechanisms that link apparently unrelated diseases, with the idea that certain molecularly targeted strategies could moderate multiple risks in obesity. We voice concern that low socioeconomic status citizens are particularly at risk for cardiometabolic disease and obesity-associated cancer, in part because many such individuals live in inflammatory and obesogenic environments. An integrated and hypothesis-driven approach is needed to study and protect these vulnerable and underserved populations from the rising tide of obesity-associated cancer.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM, Byrd-Holt DD (1998) Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care 21(4):518–524
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348(17):1625–1638
Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4(8):579–591
Wiseman M (2008) The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Proc Nutr Soc 67(3):253–256
Calle EE, Thun MJ (2004) Obesity and cancer. Oncogene 23(38):6365–6378
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371(9612):569–578
Centers for Disease Control and Prevention (CDC) (2010) Vital signs: state-specific obesity prevalence among adults—United States, 2009. MMWR Morb Mortal Wkly Rep 59(30):951–955. Most recent update: http://www.cdc.gov/obesity/downloads/DNPAO_State_Obesity_Prevalence_Map_2011_508.pdf
Haslam DW, James WP (2005) Obesity. Lancet 366(9492):1197–1209
Hossain P, Kawar B, El Nahas M (2007) Obesity and diabetes in the developing world—a growing challenge. N Engl J Med 356(9):213–215
Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27(5):1047–1053
Shaw JE, Sicree RA, Zimmet PZ (2010) Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87(1):4–14
Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, Singh GM, Gutierrez HR, Lu Y, Bahalim AN, Farzadfar F, Riley LM, Ezzati M, Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Body Mass Index) (2011) National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 377(9765):557–567
Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS (2003) Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289(1):76–79
Frederich RC, Hamann A, Anderson S, Löllmann B, Lowell BB, Flier JS (1995) Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med 1(12):1311–1314
Myers MG Jr, Heymsfield SB, Haft C, Kahn BB, Laughlin M, Leibel RL, Tschöp MH, Yanovski JA (2012) Challenges and opportunities of defining clinical leptin resistance. Cell Metab 15(2):150–156
Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G (2003) Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-α expression. Diabetes 52(7):1779–1785
Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J et al (2002) Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277(29):25863–25866
Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86(5):1930–1935
Matsubara M, Maruoka S, Katayose S (2002) Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol 147(2):173–180
Mojiminiyi OA, Abdella NA, Al Arouj M, Ben Nakhi A (2007) Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with type 2 diabetes. Int J Obes (Lond) 31(2):213–220
Snijder MB, Heine RJ, Seidell JC, Bouter LM, Stehouwer CD, Nijpels G, Funahashi T, Matsuzawa Y, Shimomura I, Dekker JM (2006) Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: the Hoorn Study. Diabetes Care 29(11):2498–2503
Agil A, Rosado I, Ruiz R, Figueroa A, Zen N, Fernández-Vázquez G (2012) Melatonin improves glucose homeostasis in young Zucker diabetic fatty rats. J Pineal Res 52(2):203–210
Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-1, IGF binding protein-3 and cancer risk: systematic review and meta-regression analysis. Lancet 363(9418):1346–1353
Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R (2009) Diabetes and cancer. Endocr Relat Cancer 16(4):1103–1123
Cohen DH, LeRoith D (2012) Obesity, type 2 diabetes and cancer: the insulin and insulin-like growth factor connection. Endocr Relat Cancer 19(5):F27–F45
Lautenbach A, Budde A, Wrann CD, Teichmann B, Vieten G, Karl T, Nave H (2009) Obesity and the associated mediators leptin, estrogen and IGF-1 enhance the cell proliferation and early tumorigenesis of breast cancer cells. Nutr Cancer 61(4):484–491
Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B, Hood N (2002) Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20(1):42–51
Aparicio T, Kotelevets L, Tsocas A, Laigneau JP, Sobhani I, Chastre E, Lehy T (2005) Leptin stimulates the proliferation of human colon cancer cells in vitro but does not promote the growth of colon cancer xenografts in nude mice or intestinal tumorigenesis in ApcMin/+ mice. Gut 54(8):1136–1145
Frankenberry KA, Skinner H, Somasundar P, McFadden DW, Vona-Davis LC (2006) Leptin receptor expression and cell signaling in breast cancer. Int J Oncol 28(4):985–993
Laud K, Gourdou I, Pessemesse L, Peyrat JP, Djiane J (2002) Identification of leptin receptors in human breast cancer: functional activity in the T47-D breast cancer cell line. Mol Cell Endocrinol 188(1–2):219–226
Valle A, Sastre-Serra J, Oliver J, Roca P (2011) Chronic leptin treatment sensitizes MCF-7 breast cancer cells to estrogen. Cell Physiol Biochem 28(5):823–832
Attoub S, Noe V, Pirola L, Bruyneel E, Chastre E, Mareel M, Wymann MP, Gespach C (2000) Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, rho-, and rac-dependent signaling pathways. FASEB J 14(14):2329–2338
Catalano S, Marsico S, Giordano C, Mauro L, Rizza P, Panno ML, Andò S (2003) Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J Biol Chem 278(31):28668–28676
Nkhata KJ, Ray A, Schuster TF, Grossmann ME, Cleary MP (2009) Effects of adiponectin and leptin co-treatment on human breast cancer cell growth. Oncol Rep 21(6):1611–1619
Price RS, Cavazos DA, De Angel RE, Hursting SD, deGraffenried LA (2012) Obesity-related systemic factors promote an invasive phenotype in prostate cancer cells. Prostate Cancer Prostatic Dis 15(2):135–143
Zheng Q, Hursting SD, Reizes O (2012) Leptin regulates cyclin D1 in luminal epithelial cells of mouse MMTV-Wnt-1 mammary tumors. J Cancer Res Clin Oncol 138(9):1607–1612
Cleary MP, Phillips FC, Getzin SC, Jacobson TL, Jacobson MK, Christensen TA, Juneja SC, Grande JP, Maihle NJ (2003) Genetically obese MMTV-TGF-α/LepobLepob female mice do not develop mammary tumors. Breast Cancer Res Treat 77(3):205–215
Grossmann ME, Cleary MP (2012) The balance between leptin and adiponectin in the control of carcinogenesis—focus on mammary tumorigenesis. Biochimie 94(10):2164–2171
Zheng Q, Dunlap SM, Zhu J, Downs-Kelly E, Rich J, Hursting SD, Berger NA, Reizes O (2011) Leptin deficiency suppresses MMTV-Wnt-1 mammary tumor growth in obese mice and abrogates tumor initiating cell survival. Endocr Relat Cancer 18(4):491–503. Erratum in Endocr Relat Cancer 18(5):X1
Cust AE, Kaaks R, Friedenreich C, Bonnet F, Laville M, Lukanova A et al (2007) Plasma adiponectin levels and endometrial cancer risk in pre- and post-menopausal women. J Clin Endocrinol Metab 92(1):255–263
Fenton JI, Birmingham JM (2010) Adipokine regulation of colon cancer: adiponectin attenuates interleukin-6-induced colon carcinoma cell proliferation via STAT-3. Mol Carcinog 49(7):700–709
Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G, Trichopoulos D (2004) Adiponectin and breast cancer risk. J Clin Endocrinol Metab 89(3):1102–1107
Dalamaga M, Diakopoulos KN, Mantzoros CS (2012) The role of adiponectin in cancer: a review of current evidence. Endocr Rev 33(4):547–594
Jardé T, Caldefie-Chézet F, Goncalves-Mendes N, Mishellany F, Buechler C, Penault-Llorca F, Vasson MP (2009) Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies. Endocr Relat Cancer 16(4):1197–1210
Jardé T, Perrier S, Vasson MP, Caldefie-Chézet F (2011) Molecular mechanisms of leptin and adiponectin in breast cancer. Eur J Cancer 47(1):33–43
Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, Vidal H, Hainque B (2000) Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 85(9):3338–3342
Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P (2004) Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 110(12):1564–1571
Wellen KE, Hotamisligil GS (2003) Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 112(12):1785–1788
Anderson EK, Gutierrez DA, Hasty AH (2010) Adipose tissue recruitment of leukocytes. Curr Opin Lipidol 21(3):172–177
Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112(12):1796–1808
Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ et al (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112(12):1821–1830
Zeyda M, Gollinger K, Kriehuber E, Kiefer FW, Neuhofer A, Stulnig TM (2010) Newly identified adipose tissue macrophage populations in obesity with distinct chemokine and chemokine receptor expression. Int J Obes (Lond) 34(12):1684–1694
Dalmas E, Rouault C, Abdennour M, Rovere C, Rizkalla S et al (2011) Variations in circulating inflammatory factors are related to changes in calorie and carbohydrate intakes early in the course of surgery-induced weight reduction. Am J Clin Nutr 94(2):450–458
Cancello R, Clément K (2006) Is obesity an inflammatory illness? Role of low-grade inflammation and macrophage infiltration in human white adipose tissue. BJOG 113(10):1141–1147
Clément K, Viguerie N, Poitou C et al (2004) Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J 18(14):1657–1669
Illán-Gómez F, Gonzálvez-Ortega M, Orea-Soler I, Alcaraz-Tafalla MS, Aragón-Alonso A, Pascual-Díaz M, Pérez-Paredes M, Lozano-Almela ML (2012) Obesity and inflammation: change in adiponectin, C-reactive protein, tumour necrosis factor-alpha and interleukin-6 after bariatric surgery. Obes Surg 22(6):950–955
Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259(5091):87–91
Nikolajczyk BS, Jagannathan-Bogdan M, Denis GV (2012) The outliers become a stampede as immunometabolism reaches a tipping point. Immunol Rev 249(1):253–275
Cinti SMG, Barbatelli G, Murano I, Ceresi E, Faloia E, Wang S, Fortier M, Greenberg AS, Obin MS (2005) Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 46(1):2347–2355
Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, Kitazawa S, Miyachi H, Maeda S, Egashira K, Kasuga M (2006) MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116(6):1494–1505
Kim CS, Park HS, Kawada T, Kim JH, Lim D, Hubbard NE, Kwon BS, Erickson KL, Yu R (2006) Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes (Lond) 30(9):1347–1355
Kintscher U, Hartge M, Hess K, Foryst-Ludwig A, Clemenz M et al (2008) T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol 28(7):1304–1310
Lê KA, Mahurkar S, Alderete TL, Hasson RE, Adam TC, Kim JS, Beale E, Xie C, Greenberg AS, Allayee H, Goran MI (2011) Subcutaneous adipose tissue macrophage infiltration is associated with hepatic and visceral fat deposition, hyperinsulinemia, and stimulation of NF-κB stress pathway. Diabetes 60(11):2802–2809
Rausch ME, Weisberg S, Vardhana P, Tortoriello DV (2008) Obesity in C57BL/6J mice is characterized by adipose tissue hypoxia and cytotoxic T-cell infiltration. Int J Obes (Lond) 32:451–463
Strissel KJ, Stancheva Z, Miyoshi H, Perfield JW II, DeFuria J, Jick Z, Greenberg AS, Obin MS (2007) Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes 56(12):2910–2918
Strissel KJ, DeFuria J, Shaul ME, Bennett G, Greenberg AS, Obin MS (2010) T-cell recruitment and Th1 polarization in adipose tissue during diet-induced obesity in C57BL/6 mice. Obesity (Silver Spring) 18(10):1918–1925
Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B (2006) Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 17(1):4–12
Kahn SE, Zinman B, Haffner SM, O’Neill MC et al (2006) Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. Diabetes 55(8):2357–2364
Di Gregorio GB, Yao-Borengasser A, Rasouli N, Varma V, Lu T, Miles LM, Ranganathan G, Peterson CA, McGehee RE, Kern PA (2005) Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes 54(8):2305–2313
Keophiphath M, Achard V, Henegar C, Rouault C, Clément K, Lacasa D (2009) Macrophage-secreted factors promote a profibrotic phenotype in human preadipocytes. Mol Endocrinol 23(1):11–24
Apovian CM, Bigornia S, Mott M, Meyers MR, Ulloor J, Gagua M, McDonnell M, Hess D, Joseph L, Gokce N (2008) Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc Biol 28(9):1654–1659
Klöting N, Fasshauer M, Dietrich A, Kovacs P, Schön MR, Kern M, Stumvoll M, Blüher M (2010) Insulin-sensitive obesity. Am J Physiol Endocrinol Metab 299(3):E506–E515
Permana PA, Menge C, Reaven PD (2006) Macrophage-secreted factors induce adipocyte inflammation and insulin resistance. Biochem Biophys Res Commun 341(2):507–514
Wentworth JM, Naselli G, Brown WA, Doyle L, Phipson B, Smyth GK, Wabitsch M, O’Brien PE, Harrison LC (2010) Pro-inflammatory CD11c+CD206+ adipose tissue macrophages are associated with insulin resistance in human obesity. Diabetes 59(7):1648–1656
Lumeng CN, Deyoung SM, Saltiel AR (2007) Macrophages block insulin action in adipocytes by altering expression of signaling and glucose transport proteins. Am J Physiol Endocrinol Metab 292(1):E166–E174
Westcott DJ, Delproposto JB, Geletka LM, Wang T, Singer K, Saltiel AR, Lumeng CN (2009) MGL1 promotes adipose tissue inflammation and insulin resistance by regulating 7/4hi monocytes in obesity. J Exp Med 206(13):3143–3156
Blüher M (2010) The distinction of metabolically ‘healthy’ from ‘unhealthy’ obese individuals. Curr Opin Lipidol 21(1):38–43
Lumeng CN, Bodzin JL, Saltiel AR (2007) Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 117(1):175–184
Duffield J (2003) The inflammatory macrophage: a story of Jekyll and Hyde. Clin Sci (Lond) 104(1):27–38
Surmi BK, Hasty AH (2010) The role of chemokines in recruitment of immune cells to the artery wall and adipose tissue. Vascul Pharmacol 52(1–2):27–36
Wu H, Ghosh S, Perrard XD, Feng L, Garcia GE, Perrard JL et al (2007) T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation 115(8):1029–1038
Loke P, MacDonald AS, Robb A, Maizels RM, Allen JE (2000) Alternatively activated macrophages induced by nematode infection inhibit proliferation via cell-to-cell contact. Eur J Immunol 30(9):2669–2678
Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, Ohsugi M et al (2009) CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 15(8):914–920
Winer S, Paltser G, Chan Y, Tsui H, Engleman E, Winer D, Dosch HM (2009) Obesity predisposes to Th17 bias. Eur J Immunol 39(9):2629–2635
Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A, Lee J, Goldfine AB, Benoist C, Shoelson S, Mathis D (2009) Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 15(8):930–939
Jagannathan M, McDonnell M, Liang Y, Hasturk H, Hetzel J, Rubin D, Kantarci A, Van Dyke TE, Ganley-Leal LM, Nikolajczyk BS (2010) Toll-like receptors regulate B cell cytokine production in patients with diabetes. Diabetologia 53(7):1461–1471
Nikolajczyk BS (2010) B cells as under-appreciated mediators of non-auto-immune inflammatory disease. Cytokine 50(3):234–242
Perreault M, Marette A (2001) Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med 7(10):1138–1143
Saberi M, Woods NB, de Luca C, Schenk S, Lu JC, Bandyopadhyay G, Verma IM, Olefsky JM (2009) Hematopoietic cell-specific deletion of toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed mice. Cell Metab 10(5):419–429
Aron-Wisnewsky J, Tordjman J, Poitou C, Darakhshan F, Hugol D, Basdevant A, Aissat A, Guerre-Millo M, Clément K (2009) Human adipose tissue macrophages: m1 and m2 cell surface markers in subcutaneous and omental depots and after weight loss. J Clin Endocrinol Metab 94(11):4619–4623
Centers for Disease Control and Prevention (2004) Cigarette smoking among adults—United States, 2000. MMWR Morb Mortal Wkly Rep 53:427–431
U.S. Department of Health and Human Services (2004) The health consequences of smoking: a report of the Surgeon General. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA
McLaughlin T, Lamendola C, Liu A, Abbasi F (2011) Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity. J Clin Endocrinol Metab 96(11):E1756–E1760
Preis SR, Massaro JM, Robins SJ, Hoffmann U, Vasan RS et al (2010) Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study. Obesity (Silver Spring) 18(11):2191–2198
Berg AH, Scherer PE (2005) Adipose tissue, inflammation, and cardiovascular disease. Circ Res 96(9):939–949
Després JP, Lemieux I (2006) Abdominal obesity and metabolic syndrome. Nature 444(7121):881–887
Hardy OT, Perugini RA, Nicoloro SM, Gallagher-Dorval K, Puri V, Straubhaar J, Czech MP (2011) Body mass index-independent inflammation in omental adipose tissue associated with insulin resistance in morbid obesity. Surg Obes Relat Dis 7(1):60–67
Kabat GC, Kim MY, Strickler HD, Shikany JM, Lane D, Luo J, Ning Y, Gunter MJ, Rohan TE (2012) A longitudinal study of serum insulin and glucose levels in relation to colorectal cancer risk among postmenopausal women. Br J Cancer 106(1):227–232
Bonora E, Willeit J, Kiechl S, Oberhollenzer F, Egger G, Bonadonna R, Muggeo M (1998) U-shaped and J-shaped relationships between serum insulin and coronary heart disease in the general population. The Bruneck Study. Diabetes Care 21(2):221–230
Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, Sowers MR (2008) The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med 168(15):1617–1624
Blüher M, Bashan N, Shai I, Harman-Boehm I, Tarnovscki T et al (2009) Activated Ask1-MKK4-p38MAPK/JNK stress signaling pathway in human omental fat tissue may link macrophage infiltration to whole-body insulin sensitivity. J Clin Endocrinol Metab 94(7):2507–2515
Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G (1997) Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest 100(5):1166–1173
Romano M, Guagnano MT, Pacini G, Vigneri S, Falco A, Marinopiccoli M, Manigrasso MR, Basili S, Davì G (2003) Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women. J Clin Endocrinol Metab 88(11):5321–5326
Sims EA (2001) Are there persons who are obese, but metabolically healthy? Metabolism 50(12):1499–1504. Erratum in Metabolism 51(4):536 (2002)
Karelis AD, Faraj M, Bastard JP, St-Pierre DH, Brochu M, Prud’homme D, Rabasa-Lhoret R (2005) The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab 90(7):4145–4150
Succurro E, Marini MA, Frontoni S, Hribal ML, Andreozzi F, Lauro R, Perticone F, Sesti G (2008) Insulin secretion in metabolically obese, but normal weight, and in metabolically healthy but obese individuals. Obesity (Silver Spring) 16(8):1881–1886
Karin M, Greten FR (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5(10):749–759
Karin M (2009) NF-κB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol 1(5):a000141
Kraus S, Arber N (2009) Inflammation and colorectal cancer. Curr Opin Pharmacol 9(4):405–410
Denis GV (2010) Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammation. Discov Med 10(55):489–499
Belkina AC, Nikolajczyk BS, Denis GV (2013) BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair macrophage inflammatory responses. J Immunol. 2013 Feb 18. E-pub ahead of print
Denis GV, Green MR (1996) A novel, mitogen-activated nuclear kinase is related to a Drosophila developmental regulator. Genes Dev 10(3):261–271
Kanno T, Kanno Y, Siegel RM, Jang MK, Lenardo MJ, Ozato K (2004) Selective recognition of acetylated histones by bromodomain proteins visualized in living cells. Mol Cell 13(1):33–43
Nakamura Y, Umehara T, Nakano K, Jang MK, Shirouzu M et al (2007) Crystal structure of human BRD2 bromodomain: Insight into dimerization and recognition of acetylated histone H4. J Biol Chem 282(6):4193–4201
Umehara T, Nakamura Y, Jang MK, Nakano K, Tanaka A, Ozato K, Padmanabhan B, Yokoyama S (2010) Structural basis for acetylated histone H4 recognition by the human BRD2 bromodomain. J Biol Chem 285(10):7610–7618
Holstege FC, Jennings EG, Wyrick JJ, Lee TI, Hengartner CJ, Green MR, Golub TR, Lander ES, Young RA (1998) Dissecting the regulatory circuitry of a eukaryotic genome. Cell 95(5):717–728
Haynes SR, Dollard C, Winston F, Beck S, Trowsdale J, Dawid IB (1992) The bromodomain: a conserved sequence found in human, Drosophila and yeast proteins. Nucleic Acids Res 20(10):2603
Tamkun JW, Deuring R, Scott MP, Kissenger M, Pattatucci AM, Kaufman TC, Kennison JA (1992) Brahma—a regulator of Drosophila homeotic genes structurally related to the yeast transcriptional activator SWI2/SNF2. Cell 68(3):561–572
Dhalluin C, Carlson JE, Zeng L, He C, Aggarwal AK, Zhou M-M (1999) Structure and ligand of a histone acetyltransferase bromodomain. Nature 399(6735):491–496
Jeanmougin F, Wurtz J-M, Le Douarin B, Chambon P, Losson R (1997) The bromodomain revisited. Trends Biochem Sci 22(5):151–153
Sanchez R, Zhou M-M (2009) The role of human bromodomains in chromatin biology and gene transcription. Curr Opin Drug Discov Dev 12(5):659–665
Beck S, Hanson I, Kelly A, Pappin DJC, Trowsdale J (1992) A homologue of the Drosophila female sterile homeotic (fsh) gene in the class II region of the human MHC. DNA Seq 2(4):203–210
Guo N, Faller DV, Denis GV (2000) Activation-induced nuclear translocation of RING3. J Cell Sci 113(pt17):3085–3091
Dey A, Chitsaz F, Abbasi A, Misteli T, Ozato K (2003) The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc Natl Acad Sci U S A 100(15):8758–8763
LeRoy G, Rickards B, Flint SJ (2008) The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription. Mol Cell 30(1):51–60
Wu SY, Chiang CM (2007) The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J Biol Chem 282(18):13141–13145
Denis GV, Vaziri C, Guo N, Faller DV (2000) RING3 kinase transactivates promoters of cell cycle regulatory genes through E2F. Cell Growth Differ 11(8):417–424
Dey A, Ellenberg J, Farina A, Coleman AE, Maruyama T, Sciortino S, Lippincott-Schwartz J, Ozato K (2000) A bromodomain protein, MCAP, associates with mitotic chromosomes and affects G2-to-M transition. Mol Cell Biol 20:6537–6549
Maruyama T, Farina A, Dey A, Cheong J, Bermudez VP, Tamura T, Sciortino S, Shuman J, Hurwitz J, Ozato K (2002) A Mammalian bromodomain protein, Brd4, interacts with replication factor C and inhibits progression to S phase. Mol Cell Biol 22(18):6509–6520
Peng J, Dong W, Chen L, Zou T, Qi Y, Liu Y (2007) Brd2 is a TBP-associated protein and recruits TBP into E2F-1 transcriptional complex in response to serum stimulation. Mol Cell Biochem 294(1–2):45–54
Sinha A, Faller DV, Denis GV (2005) Bromodomain analysis of Brd2-dependent transcriptional activation of cyclin A. Biochem J 387(pt 1):257–269
Kubonishi I, Takehara N, Iwata J, Sonobe H, Ohtsuki Y, Abe T, Miyoshi I (1991) Novel t(15;19)(q15;p13) chromosome abnormality in a thymic carcinoma. Cancer Res 51(12):3327–3328
French CA, Miyoshi I, Kubonishi I, Grier HE, Perez-Atayde AR, Fletcher JA (2003) BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res 63(2):304–307
French CA, Ramirez CL, Kolmakova J, Hickman TT, Cameron MJ et al (2008) BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene 27(15):2237–2242
Muller S, Filippakopoulos P, Knapp S (2011) Bromodomains as therapeutic targets. Expert Rev Mol Med 13:e29
Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM et al (2010) Selective inhibition of BET bromodomains. Nature 468(7327):1067–1073
Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI et al (2011) Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478(7370):529–533
Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM et al (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146(6):904–917
Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, Bergeron L, Sims RJ III (2011) Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A 108(40):16669–16674
Belkina AC, Denis GV (2012) BET domain co-regulators in obesity, inflammation and cancer. Nat Rev Cancer 12(7):465–477
Greenwald R, Tumang JR, Sinha A, Currier N, Cardiff RD, Rothstein TL, Faller DV, Denis GV (2004) Eμ-BRD2 transgenic mice develop B cell lymphoma and leukemia. Blood 103(4):1475–1484
Lenburg ME, Sinha A, Faller DV, Denis GV (2007) Tumor-specific and proliferation-specific gene expression typifies murine transgenic B cell lymphomagenesis. J Biol Chem 282(7):4803–4811
Wang F, Liu H, Blanton WP, Belkina A, LeBrasseur NK, Denis GV (2009) Brd2 disruption in mice causes severe obesity without type 2 diabetes. Biochem J 425(1):7–83
Belkina AC, Blanton W, Wang F, Liu H, Denis GV (2010) Whole body Brd2 deficiency protects obese mice from insulin resistance by creating a low inflammatory environment. Obesity 18:S58
Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW, Chandwani R et al (2010) Suppression of inflammation by a synthetic histone mimic. Nature 468(7327):1119–1123
Wang F, Deeney JT, Denis GV (2013) Brd2 gene disruption causes ‘metabolically healthy’ obesity: epigenetic and chromatin-based mechanisms that uncouple obesity from type 2 diabetes. Vitam Horm 91:49–75
Denis GV, Nikolajczyk BN, Schnitzler GR (2010) An emerging role for bromodomain-containing proteins in chromatin regulation and transcriptional control of adipogenesis. FEBS Lett 584:3260–3268
Rauchhaus M, Koloczek V, Volk H, Kemp M, Niebauer J, Francis DP, Coats AJ, Anker SD (2000) Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int J Cardiol 76(2–3):125–133
Plata-Salamán CR (2000) Central nervous system mechanisms contributing to the cachexia-anorexia syndrome. Nutrition 16(10):1009–1012
Jensen GL (2008) Inflammation: roles in aging and sarcopenia. JPEN J Parenter Enteral Nutr 32(6):656–669
Leng S, Chaves P, Koenig K, Walston J (2002) Serum interleukin-6 and hemoglobin as physiological correlates in the geriatric syndrome of frailty: a pilot study. J Am Geriatr Soc 50(7):1268–1271
Leng SX, Cappola AR, Andersen RE, Blackman MR, Koenig K, Blair M, Walston JD (2004) Serum levels of insulin-like growth factor-1 (IGF-1) and dehydroepiandrosterone sulfate (DHEA-S), and their relationships with serum interleukin-6, in the geriatric syndrome of frailty. Aging Clin Exp Res 16(2):153–157
Leng SX, Xue QL, Tian J, Walston JD, Fried LP (2007) Inflammation and frailty in older women. J Am Geriatr Soc 55(6):864–871
Lobstein T, Baur L, Uauy R, IASO International Obesity Task Force (2004) Obesity in children and young people: a crisis in public health. Obes Rev 5(S1):4–104
Figueroa-Munoz JI, Chinn S, Rona RJ (2001) Association between obesity and asthma in 4–11 year old children in the UK. Thorax 56(2):133–137
Morgan WJ, Crain EF, Gruchalla RS, O’Connor GT, Kattan M, Evans R III, Stout J, Malindzak G, Smartt E, Plaut M, Walter M, Vaughn B, Mitchell H, Inner-City Asthma Study Group (2004) Results of a home-based environmental intervention among urban children with asthma. N Engl J Med 351(11):1068–1080
Digenis-Bury EC, Brooks DR, Chen L, Ostrem M, Horsburgh CR (2008) Use of a population-based survey to describe the health of Boston public housing residents. Am J Public Health 98(1):85–91
Brugge D, Rice PW, Terry P, Howard L, Best J (2001) Housing conditions and respiratory health in a Boston public housing community. New Solut 11(2):149–164
Booth KM, Pinkston MM, Poston WS (2005) Obesity and the built environment. J Am Diet Assoc 105(5 suppl 1):S110–S117
Gennuso J, Epstein LH, Paluch RA, Cerny F (1998) The relationship between asthma and obesity in urban minority children and adolescents. Arch Pediatr Adolesc Med 152(12):1197–1200
Luder E, Melnik TA, Dimaio M (1998) Association of being overweight with greater asthma symptoms in inner city black and Hispanic children. J Pediatr 132(4):699–703
Stenius-Aarniala B, Poussa T, Kvarnstrom J, Gronlund EL, Ylikahri M, Mustajoki P (2000) Immediate and long term effects of weight reduction in obese people with asthma: randomised controlled study. BMJ 320(7238):827–832
Ma J, Xiao L, Knowles SB (2010) Obesity, insulin resistance and the prevalence of atopy and asthma in US adults. Allergy 65(11):1455–1463
Battaglia TA, Murrell SS, Bhosrekar SG, Caron SE, Bowen DJ, Smith E, Kalish R, Rorie JA (2012) Connecting Boston’s public housing developments to community health centers: who’s ready for change? Prog Community Health Partnersh 6(3):239–248
Conroy K, Sandel M, Zuckerman B (2010) Poverty grown up: how childhood socioeconomic status impacts adult health. J Dev Behav Pediatr 31(2):154–160
Trotter LJ, Bowen DJ, Beresford SA (2010) Testing for racial/ethnic differences in the association between childhood socioeconomic position and adult adiposity. Am J Public Health 100(6):1088–1094
American Cancer Society (2000) Cancer facts and figures 2000. American Cancer Society, Atlanta, GA
Barbeau EM, Kreiger N, Soobader MJ (2004) Working class matters: socioeconomic disadvantage, race/ethnicity, gender, and smoking in NHIS 2000. Am J Public Health 94(2):269–278
Blüher M (2012) Are there still healthy obese patients? Curr Opin Endocrinol Diabetes Obes 19(5):341–346
Combs TP, Pajvani UB, Berg AH, Lin Y, Jelicks LA et al (2004) A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 145(1):367–383
Acknowledgements
The authors thank the National Institutes of Health (DK090455, GVD and DK0704192, DJB), the US Centers for Disease Control and Prevention (U48 DP001922, DJB), the American Cancer Society (RSG-05-072-01, GVD), the Leukemia and Lymphoma Society (6023-09, GVD), the Boston University Clinical and Translational Science Institute (UL1-TR000157, GVD), and the Evans Center for Biomedical Research. The authors are members of an Evans Center-sponsored, multidisciplinary research collaborative, entitled “Obesity, Inflammation and Cancer” based at Boston University. GVD is a former Chair of the Basic Science Section of The Obesity Society and gratefully acknowledges the intellectual and financial support of the Society and its demonstrated and ongoing commitment to address the problem of obesity-associated cancer.
The authors report no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Denis, G.V., Bowen, D.J. (2013). Uncoupling Obesity from Cancer: Bromodomain Co-regulators That Control Inflammatory Networks. In: Dannenberg, A., Berger, N. (eds) Obesity, Inflammation and Cancer. Energy Balance and Cancer, vol 7. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6819-6_3
Download citation
DOI: https://doi.org/10.1007/978-1-4614-6819-6_3
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-6818-9
Online ISBN: 978-1-4614-6819-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)